Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leuprolide acetate + bicalutamide is a combination therapy used primarily for the treatment of metastatic prostate cancer. Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses the production of testosterone by downregulating pituitary secretion of luteinizing hormone, leading to medical castration. Bicalutamide is a nonsteroidal antiandrogen that blocks androgen receptors, preventing testosterone from stimulating prostate cancer cell growth. This combination is commonly used to achieve maximal androgen blockade and reduce tumor flare associated with initial GnRH agonist therapy[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leuprolide acetate + bicalutamide.